Company: MIRM
Filing Date: 2025-12-08
Form Type: 8-K
Source: 0001193125-25-310611
Chunk: 0

Company: Mirum Pharmaceuticals, Inc.
Filing Date: 2025-12-08
Form: 8-K
Item: Item 3.02
Chunk 0
---
Item 3.02      Unregistered Sales of Equity Securities.  

To the extent required by Form8-K, the disclosures regarding Stock Consideration under the heading “ Agreement and Plan of Merger and Reorganization” and the disclosures under the heading “ Private Placement” in Item 1.01 of this Form8-Kare incorporated into this Item 3.02 by reference.

Based in part upon the representations of the Target security holders in suitability documentation to be delivered by the Target security holders as a condition to receipt of their respective Stock Consideration, the issuance of the Stock Consideration will be issued in a transaction exempt from registration under the Securities Act by reason of Rules 504 and 506 of Regulation D promulgated under the Securities Act. The suitability documentation to be delivered by the Target security holders will include representations as to whether such Target security holders are accredited investors, as such term is defined in Rule 501(a) of Regulation D under the Securities Act, and that they are acquiring the Stock Consideration for investment for their own account and with no present intention of selling, granting any participation in, or otherwise distributing the Stock Consideration in violation of the U. S. federal securities laws.

Based in part upon the representations of the PIPE Investors in the Subscription Agreement, the offering and sale of the securities in the Private Placement will be made in reliance on the exemption afforded by Section 4(a)(2) of the Securities Act, and corresponding provisions of applicable state securities or “blue sky” laws. The PIPE Investors represented that they are accredited investors, as such term is defined in Rule 501(a) of Regulation D under the Securities Act, and that they are acquiring the securities for investment purposes only and not with a view to any resale, distribution or other disposition of the securities in violation of the U. S. federal securities laws.

The securities to be issued in the Mergers and the Private Placement will not be registered under the Securities Act or any state securities laws upon issuance and may not be offered or sold in the United States absent registration under the Securities Act or an applicable exemption from the registration requirements. The issuance of the Stock Consideration and the sale of the securities in the Private Placement did not involve a public offering and will be made without general solicitation or general advertising.

Neither this Current Report on Form 8-K nor anyexhibit attached hereto is an offer to sell or the solicitation of an offer to buy shares of Common Stock or other securities of the Company.